Background: Recent studies show that most systemic mastocytosis (SM) patients, including indolent SM (ISM) with (ISMs+) and without skin lesions (ISMs-), carry the KIT D816V mutation in PB leukocytes. We investigated the potential association between the degree of involvement of BM hematopoiesis by the KIT D816V mutation and the distribution of different maturation-associated compartments of bone marrow (BM) and peripheral blood (PB) CD34 hematopoietic precursors (HPC) in ISM and identified the specific PB cell compartments that carry this mutation.
Methods: The distribution of different maturation-associated subsets of BM and PB CD34 HPC from 64 newly diagnosed (KIT-mutated) ISM patients and 14 healthy controls was analyzed by flow cytometry. In 18 patients, distinct FACS-purified PB cell compartments were also investigated for the KIT mutation.
Results: ISM patients showed higher percentages of both BM and PB MC-committed CD34 HPC vs controls, particularly among ISM cases with MC-restricted KIT mutation (ISM ); this was associated with progressive blockade of maturation of CD34 HPC to the neutrophil lineage from ISM to multilineage KIT-mutated cases (ISM ). Regarding the frequency of KIT-mutated cases and cell populations in PB, variable patterns were observed, the percentage of KIT-mutated PB CD34 HPC, eosinophils, neutrophils, monocytes and T cells increasing from ISMs- and ISMs+ to ISM patients.
Conclusion: The presence of the KIT D816V mutation in PB of ISM patients is associated with (early) involvement of circulating CD34 HPC and multiple myeloid cell subpopulations, KIT-mutated PB CD34 HPC potentially contributing to early dissemination of the disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/all.13413 | DOI Listing |
Stem Cell Rev Rep
December 2024
Etablissement Français du Sang Nouvelle Aquitaine, CS21010, Bordeaux-Cedex, 3035, France.
To ensure the preservation of functional hematopoietic stem cells (HSC) and committed progenitor cells (HPC) at + 4 °C in ex vivo expanded cord blood cell products during worldwide transportation and subsequent infusion-without the need for washing and cell concentration-we developed a conservation medium called Stabilizer of Expanded Cells (SEC), composed exclusively of injectable pharmacological products. The in vivo engraftment assay in immunodeficient mice was used to detect primitive HSCs before and after preservation at + 4 °C. In some experiments, a complex phenotype based on CD34, CD38, and CD133 expression was utilized for this purpose.
View Article and Find Full Text PDFJ Virol
December 2024
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
The human cytomegalovirus (HCMV) encoded chemokine receptor US28 plays a critical role in viral pathogenesis, mediating several processes such as cellular migration, differentiation, transformation, and viral latency and reactivation. Despite significant research examining the signal transduction pathways utilized by US28, the precise mechanism by which US28 activates these pathways remains unclear. We performed a mutational analysis of US28 to identify signaling domains that are critical for functional activities.
View Article and Find Full Text PDFImmunol Lett
December 2024
Central Institute for Experimental Medicine and Life Science, 3-25-12 Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-0821, Japan. Electronic address:
J Clin Apher
December 2024
Bloodworks Apheresis Biologics and Therapeutics, Seattle, WA, USA.
Granulocyte-colony stimulating factor (G-CSF) mobilizes hematopoietic progenitor cells (HPC) into the peripheral blood. Donor peripheral blood platelet loss has been observed during both G-CSF mobilization and apheresis collection. This study evaluates two strategies to reduce donor platelet loss, preserve product CD34+ cell yield and collection efficiency and increase volume of whole blood (WB) processed.
View Article and Find Full Text PDFTransfusion
December 2024
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Background: Flow cytometry protocols for counting fresh CD34+ cell samples are not ideal for cryopreserved products due to cryoprotectant cytotoxicity. For cryopreserved samples, often large volumes of hypotonic solutions, which can cause cell death, are used to remove the cryoprotectant with a post-thaw wash. We recently developed a novel multistep dilution method with subsequent flow cytometry analysis to allow for accurate and reproducible results.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!